Evidence
Economic evidence
Healthcare utilisation, PSP adherence, and employer productivity data supporting the ROI case for non-pharmacological care.
Non-pharmacological PSP support and medication adherence in specialty pharma (ISPOR 2023)
Analysis of 14 specialty PSPs (n=4,200) found that integrated non-pharmacological care support was associated with 18–24% higher biologic adherence at 12 months compared to medication-only support. Statistically significant across RA and PsA subgroups.
Exercise therapy and healthcare utilisation in RA — real-world analysis (JMCP, 2022)
Retrospective claims analysis (n=890) found that RA patients completing a structured exercise programme had 22% fewer rheumatology urgent visits and 14% lower annual drug costs at 18 months post-programme.
Employer productivity and inflammatory arthritis: the case for virtual exercise support (JOEM, 2023)
Survey of 320 working-age RA and axSpA patients found mean productivity loss of 6.2 hours/week. A sub-cohort completing a virtual exercise programme recovered 2.9 hours/week at programme end — a 47% reduction in work impairment.